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Abstract
Background: Alzheimer’s disease (AD) is a chronic neurodegenerative disorder and the most common form of dementia.
The major molecular risk factor for late-onset AD is expression of the e-4 allele of apolipoprotein E (apoE), the major
cholesterol transporter in the brain. The low-density lipoprotein receptor (LDLR) has the highest affinity for apoE and plays
an important role in brain cholesterol metabolism.
Methodology/Principal Findings: Using RT-PCR and western blotting techniques we found that over-expression of APP
caused increases in both LDLR mRNA and protein levels in APP transfected H4 neuroglioma cells compared to H4 controls.
Furthermore, immunohistochemical experiments showed aberrant localization of LDLR in H4-APP neuroglioma cells, Ab-
treated primary neurons, and in the PSAPP transgenic mouse model of AD. Finally, immunofluorescent staining of LDLR and
of c- and a-tubulin showed a change in LDLR localization preferentially away from the plasma membrane that was
paralleled by and likely the result of a disruption of the microtubule-organizing center and associated microtubule network.
Conclusions/Significance: These data suggest that increased APP expression and Ab exposure alters microtubule function,
leading to reduced transport of LDLR to the plasma membrane. Consequent deleterious effects on apoE uptake and
function will have implications for AD pathogenesis and/or progression.
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Introduction
Alzheimer’s disease (AD) is a chronic neurodegenerative
disorder and the most common form of dementia. Currently,
almost 50% of the population over 85 years of age suffers from
AD. Onset of the disease after age 65 is described as late-onset or
sporadic AD, which accounts for over 95% of the cases and has
an idiopathic etiology. Extracellular b-amyloid deposits in the
cores of neuronal (senile) plaques and in vessel walls, intraneu-
ronal neurofibrillary tangles, and neuroinflammation character-
ize the disease’s pathology resulting in accelerated neuron loss
and dementia [1]. Amyloid deposits are the result of abnormal
processing of the amyloid precursor protein (APP) by two
enzymes: b-a n dc-secretase. Mutations in the two presenilin
(PS) genes encoding the catalytic core of c-secretase as well as
mutations in the APP gene lead to increases or alterations in Ab,
a 38–42 amino acid peptide and the seed for, and major
component of amyloid pathology. The particular structure of
Ab42, which is the most pathogenic form, confers the ability to
s e l f - a g g r e g a t e ,o l i g o m e r i z e ,a n d ,d e p e n d e n to nt h ep r e s e n c e
apolipoprotein E (apoE), to polymerize into amyloid filaments
[2–4].
The e-4 isoform of apoE is the strongest molecular risk factor for
the development of AD. About 60–80% of AD patients have at
least one copy of apoE4 [2,4,5] and the risk for AD is increased in
an e-4 allele dose-dependent manner [6]. ApoE is a 34 kDa, 299-
amino acid glycoprotein and is the chief cholesterol transporter
in the central nervous system (CNS). It’s gene, located on
chromosome 19q13, may code for any homozygote or heterozy-
gote combination of three common isoforms, apoE2, apoE3, and
apoE4 [7,8]. In the CNS, apoE-cholesterol is principally made in
astrocytes and exported to neurons [9,10]; however, neurons can
also produce apoE-cholesterol during stress [11]. Despite the
presence of several receptors that are capable of internalizing apoE
such as low-density lipoprotein receptor (LDLR), LDLR-related
protein (LRP), apoER2, and VLDLR, in neurons apoE is mostly
imported via the LDLR [12–15].
LDLR is a membrane-spanning glycoprotein that plays a
critical role in removing LDL and VLDL from the blood [16,17].
Under low intracellular sterol levels, LDLR gene expression is
primarily and directly activated by sterol response element-binding
proteins (SREBPs) [18] and secondarily by thyroid hormone [19].
The translation of LDLR mRNA yields a 120 kDa protein that is
post-translationally modified in the Golgi apparatus into the
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divided into five regions: the N-terminal ligand-binding domain
[17,22], the epidermal growth factor precursor homology domain
[22,23], the O-linked polysaccharide domain [24] where the
protein is post-translationally modified, the membrane-spanning
domain [25–27], and the C-terminal cytoplasmic domain [25].
Upon maturation, LDLR is transported to the cell membrane
via a clathrin-coated pit vesicle [28]. On the membrane, the
ligand-binding domain is exposed extracellularly to associate
and internalize LDL or VLDL, mediated by apoB or apoE,
respectively. Once inside the cell, LDLR-ligand-containing vesicles
are acidified by proton pumps [29], leading to uncoupling of the
receptor-ligand complex. At this point, the LDL or VLDL-
cholesterol undergoes further processing to be readily available for
the cell’s requirements.
Several groups identified a potential contribution of LDLR to
AD and investigated potential links, for example by crossing AD
transgenic mice with the LDLR2/2 mouse model of hypercho-
lesterolemia to investigate the effects of LDLR deficiency [30–40].
Some apparently opposing results were obtained. Here we
investigate the effects of APP over-expression on the expression
and localization of LDLR to identify possible changes that could
result in an altered apoE metabolism. We report that over-
expression of APP in a human neuroglioma cell line increased the
amounts of LDLR mRNA and protein, and the receptor
accumulated in the perinuclear region of the APP-expressing
cells. This altered localization was specific to LDLR and could not
be seen for LRP. Furthermore, in comparing NTG with PSAPP
and APP2/2 transgenic mouse models, we found that LDLR
protein levels were directly proportional to the amount of APP.
Immunohistochemical analysis of a- and c-tubulin suggest that
alterations in LDLR are rooted in an APP-mediated disturbance
of the centrosome and microtubules, preventing proper transport
of LDLR to the plasma membrane.
Results
Initially, we sought to determine changes in the mRNA and
protein levels of LDLR in human neuroglioma cells that were
stably transfected with human wild-type APP (H4-APP) and used
their non-transfected H4 counterpart as controls. H4-APP cells
express about 12 times more APP than non-transfected controls
and it is distributed throughout the whole cell (Figure S1). RT-
PCR experiments with H4 and H4-APP cells demonstrated a
3-fold increase in LDLR mRNA in H4-APP cells compared to H4
controls (Figure 1A). This result was paralleled at the protein level
as evidenced by western blot analysis (Figure 1B). Quantification
of the immunoblots showed a 4-fold increase in LDLR protein in
H4-APP cells compared to H4 controls (Figure 1C).
Next, we performed immunofluorescence imaging on H4 and
H4-APP cells to determine changes in LDLR localization. In order
to assess whether potential APP-induced alterations were specific
to LDLR, we immunostained for LDLR and another member of
the LDLR family, LRP (LDLR-related protein-1) (Figure 2A).
Images of H4 and H4-APP cells without primary antibody
incubation are shown as a negative control of the assay (Figure 2A).
While we did not observe significant changes in the distribution
of LRP, we found that in H4-APP cells, LDLR had become
densely concentrated in the perinuclear region (indicated by
the arrowheads in panels 2A and 2B). Compared to LDLR
localization, the LRP signal was concentrated in a perinuclear
density in both H4 and H4-APP cells. At closer inspection
(Figure 2B), we confirmed that in H4 control cells, LDLR is
homogeneously distributed, whereas in H4-APP cells, LDLR
appears to converge to form a dense perinuclear core. To quantify
this effect, we defined cells displaying a dense LDLR-positive focus
as cells containing a signal that was three standard deviations
above the background and with at least 1000 pixels
2. By this
criterion, 59% of H4-APP versus 10% of H4 cells had LDLR
accumulated in the perinuclear zone of the cells. (Figure 2C;
*p=0.001). In contrast, 72% of H4-APP cells and 66% of H4 cells
displayed the dense perinuclear signal for LRP, not indicating any
significant change (Figure 2D; p=0.56).
It seems reasonable that if LDLR becomes highly concentrated
in a single perinuclear core, then there may be a relative deficit of
LDLR in its normal, physiologically relevant location on the
plasma membrane. We therefore examined H4 and H4-APP
cells with the LDLR antibody as above, but leaving out the
permeabilization step so as to only visualize cell-surface LDLR.
H4-APP cells exhibited a 32% significant reduction of plasma
membrane-associated LDLR (Figure 3A, 3B, and 3C). This result
indicated that there was likely a concomitant reduction in LDLR
function, despite the compensatory upregulation of LDLR mRNA
and protein shown in Figure 1.
AD pathology is initiated and maintained when the APP protein
becomes proteolytically cleaved to generate various forms of the
Figure 1. LDLR mRNA and protein are upregulated in H4-APP cells compared to H4 controls. (A) RT-PCR quantification of LDLR mRNA
expression level in H4 and H4-APP cells (n=3; *p=0.04). LDLR threshold cycle values were normalized to GAPDH. (B) Western blot for LDLR in whole-
cell lysates from H4 and H4-APP cells. Lane 1 contains liver whole-cell lysate from a NTG mouse. (C) Quantification of western blot (n=3; *p=0.01). All
bands for LDLR were quantified and their values shown in this graph. The LDLR band densities were normalized to the actin band in each lane. RT-
PCR and western blot experiments were conducted in triplicate.
doi:10.1371/journal.pone.0008556.g001
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pathogenic. In order to assess the general relevance of the
redistribution of the LDLR in H4-APP cells, we repeated the
experiment using cultured mouse cortical neurons from normal
mice and exposing them to 1uM of either Ab40 or Ab42 for
48 hours; as a reference, we also treated and immunostained a set
of neurons with a peptide consisting of scrambled amino acids of
the Ab42 peptide (Figure 4A and 4B). Similar to the H4-APP cells,
the Ab40- and Ab42-treated cortical neurons had 23% (*p,0.05)
and 13% (**p,0.01) less surface LDLR compared to Ab42
scrambled peptide-treated cells (Figure 3C). The amount of
surface LDLR was also significantly decreased in Ab40-treated
compared to Ab42-treated cells (10%; *p,0.05).
Thus far we have shown that the upregulated LDLR protein in
H4-APP cells cannot be accounted for on their cell membrane. To
identify the localization of the LDLR aggregate, we co-stained
LDLR with organelle markers for the Golgi apparatus (Figure 5A
and 5B), lysosomes (Figure 5C and 5D), endoplasmic reticulum
(Figure 5E and 5F), and early endosomes (Figure 5G and 5H). We
found that in H4-APP cells, LDLR signal co-localized in the Golgi
apparatus and lysosomes, or the trans-Golgi network. In contrast,
LDLR signal in the ER or endosomes was not particular to either
H4 or H4-APP cells.
We next sought to reproduce the APP-induced LDLR over-
expression and mis-localization in a physiologically relevant
experimental system—an in vivo model of AD. We chose PS1+/2
APP+/2 (PSAPP) mice at 10 months of age when their brains are
burdened with amyloid, homogenized brain tissue from the
PSAPP mice and age-matched non-transgenic (NTG) controls
and performed western blot analysis for LDLR. We observed a
modest, yet significant increase of LDLR in PSAPP mice
compared to controls (Figure 6A and 6B; 20% increase with
*p=0.05). The same experiment served to confirm that the
PSAPP mice overexpressed APP (Figure 6A). In order to further
investigate whether the LDLR protein levels are influenced by
APP expression, we performed western blots for LDLR in 10-
month old APP2/2 mice. Interestingly, we found that LDLR was
decreased by 55% in these mice compared to age-matched
controls (Figure 6C and 6D; *p=0.04). These experiments
indicate that LDLR expression directly correlates with APP
expression.
To determine if changes in LDLR expression are paralleled
by changes in its localization in PSAPP mice, we performed
Figure 2. LDLR distribution is altered in H4-APP cells compared
to H4 controls. (A) Immunohistochemistry imaging at 4006
magnification of LDLR and LRP in H4 and H4-APP cells. Red signal
corresponds to LDLR or LRP as indicated and blue signal corresponds to
Hoechst-labeled cell nuclei. Arrowheads point to three examples of a
dense perinuclear LDLR-positive signal present in H4-APP cells. (B)
Larger image of a selected cell from panel 2A; the arrowhead points to
an LDLR-positive density. (C and D) Quantification of the percentage of
cells with perinuclear density of fluorescent signal in LDLR (C) and LRP
(D), which is described in more detail in Figure S2.
doi:10.1371/journal.pone.0008556.g002
Figure 3. Cell surface LDLR is much reduced in H4-APP cells. H4
and H4-APP cells were immunostained for LDLR in the absence of
detergents to prevent permeabilization of the plasma membrane and
allow antibody access only to the cell surface. (A) Images magnified at
4006showing LDLR signal (red) and nuclei (blue) for H4 and H4-APP.
(B) Zoomed image of one cell isolated from panel A. (C) Quantification
of the average LDLR-positive signal per cell showing a 32% reduction of
LDLR on the membrane of H4-APP cells (*p=0.03). The average of the
ratio of the total LDLR intensity and the number of cell nuclei for the H4
condition was equaled to 100%. The H4-APP ratio was divided by the
H4 ratio of LDLR intensity per cell; A total of ,18,000 cells were taken
into account from three independent experiments.
doi:10.1371/journal.pone.0008556.g003
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10 months and age-matched controls. We detected an increase in
the LDLR signal in the hippocampus of PSAPP mice, a region
that is particularly affected by the amyloid pathology. This effect
was the strongest in the CA3 region of the hippocampus
(Figure 7A). At higher magnification, we found that cells
surrounding the neuronal layer of the hippocampus in PSAPP
tissues also showed a dense accumulation of LDLR similar to that
observed in H4-APP cells (arrowhead in PSAPP hippocampal cell
of figure 7A), whereas the NTG counterpart lacked that same
signal concentration (Figure 7A). After quantification of the LDLR
signal normalized to the amount of DAPI signal in each field, we
calculated a 30% increase (*p=0.04) in LDLR in the hippocampi
of PSAPP mice compared to NTG controls (Figure 7B).
The centrosome, or microtubule-organizing center (MTOC), is
responsible for the nucleation step preceding the polymerization of
microtubules and maintains the structure of the microtubule
network. It was previously reported that PS1 and APP bind to the
centrosome [41,42]. We therefore reasoned that the mechanism
behind the changes in localization and expression levels of LDLR
mRNA and protein could be based on an APP-mediated alteration
of the microtubule-trafficking system. To address this hypothesis,
we performed immunohistochemistry in H4 and H4-APP cells
targeting c-tubulin as a marker of the MTOC. While we observed
condensed staining of c-tubulin in H4 cells, H4-APP cells showed
a diffuse, non-nuclear pattern of c-tubulin signal (Figure 8A and
8B) where 0.64% of the c-tubulin signal was dispersed in H4-APP
cell. In contrast, 0.72% percent of the c-tubulin signal was diffuse
in the H4 cells; this was a modest change (0.08%), yet it was
significantly different (*p=0.01; Figure 8C).
Finally, to address the relationship between APP over-
expression and alterations to the mature microtubule-trafficking
network, we performed immunofluorescent staining of H4 and
H4-APP cells targeting a-tubulin as an indicator of microtubule
localization. We found that only 82% of the alpha-tubulin signal in
H4-APP cells was diffuse, while H4 cells had 87% of the total
a-tubulin signal spread throughout the cell (Figure 9A and 9B).
Like in the c-tubulin staining experiment, this was a modest but
significant change in signal distribution (5%; *p=0.04) between
the transgenic and non-transgenic (Figure 9C).
Discussion
Characterization of apoE metabolism in the brain is of critical
importance for development of potential therapeutic targets for
AD. Because apoE is the principal ligand for LDLR, alterations to
LDLR trafficking are likely to impact AD pathology as well. As the
main cholesterol transporter in the CNS, apoE is produced by glia
Figure 4. Ab42 reduces LDLR cell surface localization in primary neurons of NTG mice. Primary neurons were obtained from E18 fetuses,
plated and grown for one week, and treated with 1 mMA b40 or Ab42 for 48 hours. Cell surface LDLR was immunostained (red). (A) Image of primary
neurons from cells treated for 48 hours with 1mMA b42 scrambled peptide, Ab40, and Ab42; image is magnified 6306. (B) Zoomed image isolating one
cell in each field of panel A. The negative control corresponds to staining in the absence of primary antibody. Quantification as in Figure 3 revealed
statistically significant reduction in cell surface LDLR induced by exposure to Ab.
doi:10.1371/journal.pone.0008556.g004
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endocytosis via LDLR. In order for apoE-cholesterol to enter the
cell, LDLR must be localized to the plasma membrane. Our
findings indicate that in H4-APP cells and primary neurons
treated with Ab42, this localization is altered in that the majority of
LDLR signal is concentrated in a dense focus in the perinuclear
zone and is therefore hindered from reaching the plasma
membrane (Figures 2 and 3). Transcriptional activation of the
LDLR gene is normally induced by a system that is sensitive to low
levels of intracellular sterols [18]. Therefore, it is possible that the
upregulation of LDLR (Figure 1A) in H4-APP cells is a reflection
of low intracellular cholesterol due to the significant reduction of
LDLR on the cell membrane for cholesterol internalization
(Figures 3, 4). A summary diagram indicating the observed
changes in LDLR production and localization induced by APP/
Ab is shown in Figure 10.
Figure 5. LDLR is abundant in the trans-Golgi network of H4-APP cells. H4 and H4-APP cells were co-stained for LDLR and different organelle
markers. A and B show Golgi apparatus at low and high magnification, respectively. C and D show LDLR co-stained with lysosomal marker at low and
high magnification, respectively. E and F show LDLR co-stained for endosomes at low and high magnification respectively. G and H show LDLR co-
stained with endoplasmic reticulum at low and high magnification, respectively. A, C, E, and G were taken at 4006, while B, D, F, and H are zoomed
images.
doi:10.1371/journal.pone.0008556.g005
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PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8556Figure 6. Brain LDLR is increased in PSAPP mice and decreased in APP2/2 mice compared to controls. Whole-cell lysates were prepared
from brains of 10-month old PSAPP, APP2/2, and age-matched non-transgenic control mice for western blot analyses; liver whole cell lysates were
preparedfromNTGandLDLR2/2aspositiveandnegativecontrolhomogenates,respectively.(A)WesternblotforLDLR,APP,andactinfromPSAPPand
NTG control lysates. (B) Quantification of LDLR signal normalized to actin in western blot of panel A (n=5; *p=0.05). (C) Western blot for LDLR and actin
from NTG and APP2/2 mice. (D) Quantification of LDLR signal normalized to actin in western blot of panel C (nNTG=3 and nAPP2/2=4;*p=0.04).
doi:10.1371/journal.pone.0008556.g006
Figure 7. LDLR is increased and delocalized in the hippocampus of PSAPP mice compared to NTG controls. (A) Representative images
at 56magnification of immunohistochemistry staining of the CA3 region of the hippocampus and an enlarged view of a representative hippocampal
cell surrounding the neuronal layer of a PSAPP and NTG mouse. Mice were 10-month old PSAPP and NTG. LDLR signal is in red and cell nuclei are in
blue. Arrowhead in PSAPP hippocampal neuron indicates the concentration LDLR-positive signal. (B) Quantification of LDLR-positive signal
normalized by the DAPI signal in hippocampus of PSAPP and NTG mice. Experiments were done in triplicate using brain sections of 8 mice for each
condition.
doi:10.1371/journal.pone.0008556.g007
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PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8556Figure 8. c-tubulin signal is more widely distributed in H4-APP cells compared to H4 controls. (A) Immunohistochemistry imaging at
4006 magnification of LDLR and c-tubulin in H4 and H4-APP cells. Red, green, and blue signals correspond to LDLR, c-tubulin, and cell nuclei,
respectively. Arrowheads indicate three examples of H4-APP cells containing greater area of c-tubulin signal distribution. (B) Larger image of a
selected cell from the same slide. Merged images in A and B show the location of LDLR in relation to c-tubulin and the nucleus. (C) Percentage of
diffuse c-tubulin signal in H4 compared to H4-APP cells. Quantification is described in further detail in Figure S2.
doi:10.1371/journal.pone.0008556.g008
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PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8556Figure 9. a-tubulin is less widely distributed in H4-APP cells compared to H4 controls. (A) Immunohistochemistry imaging at 4006
magnification of LDLR and a-tubulin in H4 and H4-APP cells. Red, green, and blue signals correspond to LDLR, a-tubulin, and cell nuclei, respectively.
Arrowheads indicate three examples of H4-APP cells containing less diffuse a-tubulin. (B) Larger images of selected cells from panel A. Merged
images in A and B show the location of LDLR in relation to a-tubulin and the nucleus. (C) Percentage of diffuse a-tubulin signal in H4 compared to
H4-APP cells. Quantification is described in further detail in Figure S2.
doi:10.1371/journal.pone.0008556.g009
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the rate at which APP is processed into Ab. Studies using animals
fed high cholesterol diets revealed an increase in amyloid plaque
formation in rabbits and in transgenic mouse models of AD
[43,44,45]; moreover, in these mice, the high cholesterol diet
induced cognitive decline [46]. In vitro studies show that
imbalances in cellular cholesterol may favor APP cleavage by
either a-o rc-secretase. Conversely, cholesterol-depleted rat
hippocampal primary neurons show reduced APP processing into
Ab [47,48] and favor the generation of non-amyloidogenic APP
processing by a-secretase to yield the soluble, non-pathogenic
protein sAPPa [49,50]. In contrast, c-secretase processing is
favored when APP is located in the lipid raft; the result is
formation of toxic Ab peptide. Thus, the amount and distribution
of cellular cholesterol is essential for the formation of lipid rafts,
and therefore the localization and processing of APP. This
connection might also mean that if the observed increased
expression of LDLR in apparent compensation for incorrect
localization induced by APP overshoots, then more apoE-
cholesterol could be imported, leading to more APP processing
to Ab in an accelerating pathogenic cycle.
Our experiments on PSAPP mice show that LDLR and APP
protein levels are directly proportional (Figure 6). These results
together with those obtained with the H4 and H4-APP cell models
suggest that APP over-expression affects the MTOC such that
LDLR transport to the cell membrane is significantly abrogated.
Consequently, net cholesterol import into the cell could be
decreased, leading to upregulation of LDLR transcription and
protein levels. It was previously shown that APP and PS1 bind to
the centrosome [41,42]. As a result, the centrosome’s nucleation
function for microtubule formation may be disrupted by associa-
tion with excess levels of APP or Ab in our over-expression models
or by mutations of the APP gene. This in turn may have
widespread detrimental effects for the entire microtubule traffick-
ing system. Our results provide evidence that trafficking of other
proteins, organelles, or vesicles in the cell may also be disturbed,
although this cannot be true for all proteins as LRP localization
was unchanged in the H4-APP cells. (Figure 2A).
Over the past 15 years, a considerable amount of effort has been
dedicated to characterize the potential participation of LDLR in
AD pathology. This interest is based on data procured from
linkage analyses of AD risk and the LDLR gene, preliminary data
from population and case-control studies, and the importance of
LDLR function in the regulation of cholesterol homeostasis via
apoE metabolism, whose e4 allele is the most important risk factor
for ‘sporadic’ AD besides age. Linkage analyses were based on
the fact that the LDLR gene locus and a region associated
with high frequency of AD risk share a common location on
chromosome 19 [34,35]. Furthermore, this peak of risk for AD
onset is independent of the risk imparted by the nearby apoE4
gene [35]. Consequent attempts to characterize linkage of LDLR
and AD onset yielded at least ten, case-control association studies
and one family-based study [30–33,36–40,51,52]. Of particular
interest were polymorphisms contained in exons 8, 10, 13, and 15,
as they had been proposed to have associations with risk of
AD onset [33,37,39]. The overall conclusion of these studies is,
however, still developing.
Other conflicting reports have investigated LDLR’s participa-
tion in AD at the molecular level [46,53,54]. The objective of
these studies was to study whether elimination of LDLR
expression would affect the pathology in AD mice. To this end
Fryer et. al. [53] and Cao et. al. [54] crossed the LDLR2/2
Figure 10. Proposed mechanism by which APP/Ab overexpression diminishes LDLR trafficking by disrupting microtubule
formation. Overexpression of APP/Ab causes microtubule destabilization by altering the centrosome, and consequently, polymerized microtubules.
As a result, LDLR trafficking from the TGN to the plasma membrane is impaired. Therefore, LDLR accumulates in the TGN. The implications are that
the cell may be unable to import cholesterol effectively, which causes transcriptional activation of the LDLR gene.
doi:10.1371/journal.pone.0008556.g010
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respectively. Both groups agreed that LDLR is the main
regulator of apoE in CNS as they observed a significant increase
in apoE levels in the CNS of their mice. However, Fryer et. al. did
not observe changes in pathology, whereas Cao et. al. reported a
mild yet significant increase in plaque deposition. Furthermore,
this latter study also reported that the mice performed poorly on
a battery of cognitive tests. The question of whether LDLR
is involved in AD pathogenesis and/or progression remains
unanswered.
In contrast to the investigations of the role of LDLR in AD, our
approach was to determine instead the effects of amyloid
pathology on LDLR metabolism. We describe in this report that
APP/Ab over-expression in in vivo and in vitro models of AD causes
alterations to LDLR that may be explained by an APP/Ab-
mediated effect on the microtubule trafficking system. In H4-APP
cells, a human neuroglioma cell line stably over-expressing human
wild-type APP, LDLR mRNA and protein levels are increased. In
these conditions, H4-APP had LDLR aggregated in the trans-Golgi
network, which precluded its trafficking to the cell membrane.
Furthermore, Ab42 treatment also caused aggregation of the
LDLR signal. Concomitantly, the PSAPP mouse model of AD,
which over-expresses the full-length human APP containing the
V717F mutation, also shows aberrant distribution and a mild, yet
significant increase in LDLR protein. The experiments suggest
that a likely explanation for these phenomena is that H4-APP cells
have changes in the localization of the microtubule proteins a- and
c-tubulin.
The H4-APP cells and PSAPP mouse models we evaluated
emulate the APP-induced amyloidogenic effects seen in individuals
with trisomy 21. Interestingly, the serum cholesterol and lipid
profiles of these individuals are abnormal, yet they are protected
against atherosclerosis [55,56]. It would be interesting to assess
whether LDLR turnover rates are changed in different tissues of
individuals with trisomy 21.
Based on our data, we suggest that, rather than a precursor, DS
and AD dyslipidemia is a consequence of AD-like Ab and amyloid
production induced by increased APP. Indeed Ab production and
amyloid production has been shown to reduce cell surface levels of
other proteins including the NMDA receptor and the EphB2
receptor, both involved in synaptic plasticity [57,58]. Careful
evaluation of the mechanisms underlying APP processing as a
factor in cholesterol metabolism and receptor localization may
yield novel therapeutic approaches against Alzheimer’s, for
example through rescuing general receptor transport to the cell
membrane by reducing the deleterious effect of Ab on the
cytoskeleton.
Materials and Methods
Ethics Statement
All animal studies were approved by the University of South
Florida’s Institutional Animal Care and Use Committee and
abided by that Committee’s Policies on Animal Care and Use in
accordance with the Guide for the Care and Use of Laboratory
Animals, the Animal Welfare Regulations Title 9 Code of
Federal Regulations Subchapter A, ‘‘Animal Welfare’’, Parts
1–3, and the Public Health Service Policy on Humane Care and
Use of Laboratory Animals. This USF program and the
facilities for animal care and use are fully accredited by the
Association for Assessment and Accreditation of Laboratory
Animal Care International. The animals are in standard
housing on a 12-hour light dark cycle and have food and water
ad. lib.
Materials
Quantitative-PCR experiments were performed using Applied
Biosystems, PCR master mixes, human GAPDH endogenous
control assays, and gene expression assays for human LDLR (assay
ID Hs01092525_m1). Tissue culture reagents and electrophoresis
supplies were purchased from Gibco/Invitrogen. Protein concen-
trations were determined with BCA
TM (Pierce) colorimetric assays.
Ab peptides were obtained from American Peptide.
Antibodies
Rabbit anti-LDLR antiserum was a generous gift from Dr.
Joachim Herz at the University of Texas Southwestern. It
was used as primary antibody for immunoblots (1:1000) and
immunohistochemistry assays (1:100). [59]. Alternatively, a
monoclonal anti-LDLR antibody from Fitzgerald Industries
International (cat.# 10-L55A) was used for immunohistochemistry
experiments where the co-stain targets required rabbit-polyclonal
antibodies. Organelle markers for the Golgi apparatus, lysosomes,
and early endosomes (GM130, LAMP1, and EEA1 antibodies,
respectively) were purchased from Cell Signaling Technologies,
while the KDEL antibody, a marker of endoplasmic reticulum was
purchased from Stressgen. Monoclonal mouse anti-actin (Sigma-
Aldrich) and AlexaFluor 488 and 594 (Invitrogen/Molecular
Probes) antibodies were diluted according to the manufacturer for
western blot (WB) and immunohistochemistry (IHC) assays,
respectively. Goat anti-mouse IRDyeH800CW and goat anti-
rabbit IRDyeH680 were purchased from LI-COR Biosciences
(WB: 1:15,000; IHC: 1:1500). Monoclonal anti-a-tubulin and c-
tubulin antibodies were obtained from Sigma-Aldrich and diluted
according to the company’s specifications. Anti-LRP antibody was
a generous gift from Dr. Guojun Bu.
Animals
Mice with the genotype APP
+/2, PS1
+/2 were generated by
crossing heterozygous PDGF-hAPP(V717F) mice [Swiss-Webster
X C57BL/6] with PDGF-hPS1(M146L) heterozygotes [Swiss-
Webster X C57BL/6] as described [60]. Non-transgenic (NTG)
control mice for LDLR2/2 mice were C57BL/6J expressing
endogenous LDLR (The Jackson Laboratory). NTG control mice
for APP
+/2, PS1
+/2 were littermates that lacked both transgenes.
All mice were genotyped by PCR to confirm the presence or
absence of PDGF-hAPP [61] and PDGF-hPS1 [62]. APP knock
out mice (strain B6.129S7-APP
tm1Dbo/J) were obtained from
The Jackson Laboratory and were genotyped according to the
provider’s recommendations. Primary neurons were obtained
from the cortex and hippocampus of E18 NTG mice as described
[63]. Neurons were grown for one week on poly-L-lysine-coated
8-chamber slides in neurobasal medium with B27 supplement.
Neurons were then treated for 48 hours with 1 mM concentration
of either Ab40 or Ab42. Cells were then fixed and stained as
described below in the immunohistochemistry section.
Tissue Preparation
Brain tissue was acquired by anesthetizing mice with 0.1 mg/g
Nembutal followed by transcardial perfusion with 0.9% saline
solution for 8–12 min at 120 mmHg. Whole brains were
immediately removed for processing. Messenger RNA was
extracted by homogenizing tissues in TRI reagent (Sigma-
Aldrich). Microsomal protein extracts were obtained as previously
described [64], with minor modifications: 0.25M sucrose was
prepared with protease inhibitors (1 tablet mini-Complete/10 ml
sucrose, Roche Applied Science). Samples were dounce homog-
enized and spun at 10,0006g for 10 min. Then, supernatants were
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Microsome pellets were resuspended in PBS with 10% glycerol
and protease inhibitor cocktail (Roche). Brains for immunohisto-
chemistry assays were fixed for 24 hrs in 4% para-formaldehyde.
The fixed tissues were cryo-protected in successive sucrose
gradients as previously described [65]. Brains were frozen on a
temperature-controlled freezing stage, coronally sectioned (25 mm)
on a sliding microtome, and stored in a solution of PBS containing
0.02% NaN3 at 4uC.
Quantitative RT-PCR
Five micrograms of DNase-treated mRNA were reverse-
transcribed with SuperScriptH VILO
TM cDNA Synthesis Kit
(Invitrogen) using random hexamers according to the manufac-
turer’s instructions. Quantitative RT-PCR was performed accord-
ing to the manufacturer. Reactions were processed in the 7500
FAST System with its Sequence Detection Software (SDS) from
Applied Biosystems.
Western Blots
Unless otherwise indicated, 50 mg (protein) of brain microsomes
were denatured with LDS sample buffer according to the
Invitrogen protocol. Samples were loaded onto 3–8%, 1.0 or
1.5mm Tris-Acetate gels, and run at 80V for 180 min. Gels were
dry- (iBlot, Invitrogen) or wet-transferred onto PVDF membranes
for 9 min. Non-specific protein binding to the membrane was
blocked by incubating with 5% BSA or 7% non-fat dry milk for
90 min at room temperature. Primary antibody for actin was
diluted 1:10000, while a-, c-tubulin, and LDLR antibodies were
diluted 1:1000 in blocking buffer and incubated overnight at 4uC.
Secondary antibody incubations with either IR-dyes (1:15000) or
HRP-conjugated were performed sequentially for 60 min at room
temperature. Membranes were washed three times for 10 min
with PBS or TBS and 0.1% Tween-20 after incubation with each
antibody. Membranes were scanned and analyzed with the LI-
COR Odyssey and accompanying software or developed using
ECL reagent.
Immunohistochemistry
H4 and H4-APP cells were cultured in 8-chamber slides for 3
days prior to immunostaining. Cells were then fixed in ice-cold
methanol for 15 min at room temperature and incubated with
blocking buffer (described below). Brain sections were mounted
onto ColorfrostH/Plus slides (Fisher Scientific) Non-specific
binding was blocked in NGS (10% normal goat serum, 0.2%
Triton X-100, and 0.02% NaN3 in Tris-buffered saline (TBS)) or
in NGS without detergents for non-permeabilizing experiments,
for 120 min at room temperature. Primary antibodies were
incubated overnight at 4uC in 10% NGS. After four, 5 min
washes in TBS, slides were incubated with AlexaFluor 2594 and
2488 (anti-rabbit and anti-mouse, respectively) secondary
antibodies in 10% NGS for 60 min at room temperature and
washed in TBS. Slides were stained with Hoechst (1mg/ml in
PBS) for 2 min to reveal cellular nuclei and mounted using
GelMount (Fisher Scientific). Staining was analyzed with the
Zeiss AxioImager.Z1 and AxioVision software using 56/0.16 or
406/0.75 dry ECPlan-NeoFluar objectives where specified.
Images were captured at room temperature with an AxioCam
MR3 camera. Fluorochromes used were DAPI, DsRed, and
FITC. The magnified hippocampal cell image in figure 7A was
modified in Adobe Photoshop by modifying the brightness and
contrast to both the NTG and PSAPP cell images equally and
simultaneously.
Image Quantification
LDLR, LRP, c and a-tubulins, and APP were quantified using
ImageJ as described in Figure S2. Figure 3 and 4 analysis was
performed by the following procedure: images scanning the entire
well for H4, H4-APP, primary neurons, and no-primary-antibody
negative controls were obtained. These images were taken at
1006 and using the same exposure time for the channel
corresponding to LDLR. We discarded pictures containing
artifacts (such as those with cells damaged by the pipette tip),
images from the edges of the wells (due to potential artifacts
caused by the rubber gasket), and fields containing less than 200
nuclei. We obtained the integrated density (I.D.) of each field and
the number of cell nuclei using ImageJ [66,67]. We divided the
I.D. by the number of cell nuclei to generate the amount of plasma
membrane LDLR/cell (I.D./cell). The I.D./cell for the negative
control was subtracted from the I.D./cell of H4, H4-APP, or
neuronal cells. The average of the values for each condition was
compared. Over 18,000 cell nuclei were taken into account from
three independent experiments.
Statistical Analyses
All data reported were obtained from independent experiments
repeated at least three times. Data were plotted as 6SE of the
mean. P-values were obtained from paired t-test analyses.
Supporting Information
Figure S1 APP overexpression in H4-APP cells causes aberrant
localization in the cell. (A) Immunohistochemistry imaging at
4006magnification of LDLR and APP in H4 and H4-APP cells.
Red, green, and blue signals correspond to LDLR, APP, and cell
nuclei, respectively. (B) Quantification graph of diffuse APP signal
between H4 and H4-APP cells. (C) Western blot of APP in H4 vs.
H4-APP cells; actin was used as a loading control. (D)
Quantification of western blot in (C); quantification is described
in more detail in Figure S2.
Found at: doi:10.1371/journal.pone.0008556.s001 (1.41 MB TIF)
Figure S2 Quantification of staining using Image J. A)
Representative image of H4-APP cells for analysis. The cells have
been stained for LDLR. B) Histogram generated from ImageJ
based on the image shown in panel A. Pixel gray value is the color
of the pixel on a scale of 0 to 255, with 0 being absolute black and
255 being absolute white. C) Magnification of the histogram in
panel B. In this representative histogram, the mean pixel value is
11.801, and the standard deviation of the histogram is 23.217. In
order to identify the intensely stained perinuclear density, the
image was thresholded at 3 standard deviations from the mean. At
this threshold, only pixels with a gray value of 81 or greater were
identified as positive stain (dark gray region in right tail).
Identification of total cellular staining was done with the image
thresholded at 0.5 standard deviations from the mean of the
image, so all pixels with a value of 21 or greater were identified as
positive stain (light gray region and dark gray region). For tubulin
staining, staining outside of the density was defined as that falling
between 0.5 standard deviations and 3 standard deviations (light
gray region only). D) Image showing thresholding of the image
shown in panel A at 3 standard deviations. Note that only intense
staining is identified at this threshold. E) Further identification of
the intense perinuclear density based on the criterion that the
region be at least 1000 square pixels in area. F–K) Representative
image of H4 cells stained for LDLR, thresholded, and perinuclear
densities identified as described in A–E.
Found at: doi:10.1371/journal.pone.0008556.s002 (0.56 MB TIF)
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